Roy Carr Promoted to Vice President of Business Development and William Toreki to Vice President of Research & Development as Part of Management Transition
GAINESVILLE, FL -- (MARKETWIRE) -- 07/31/12 -- Quick-Med Technologies, Inc. (OTCQB: QMDT) (PINKSHEETS: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that Bernd Liesenfeld, Ph.D. has been appointed as President of the Company and as a member of its Board of Directors.
Dr. Liesenfeld joined Quick-Med in 2004 and led the development of the NIMBUS® technology used in the Bioguard line of products licensed to Derma Sciences. He has been involved in all aspects of commercializing Quick-Med's antimicrobial technologies, including biochemistry, biosafety, regulatory and production development. Dr. Liesenfeld also led the Quick-Med team that received the top industrial research prize at the 2011 Wound Healing Society meeting for U.S. Army-sponsored research that showed improved wound healing in an animal model of vesicant injury using an advanced multi-feature NIMBUS dressing. Dr. Liesenfeld received a Ph.D. in Materials Science and Engineering from the University of Florida and holds a Bachelor's degree in Mechanical Engineering and Management from the University of Vermont.
Joining Dr. Liesenfeld on Quick-Med's leadership team will be Roy D. Carr as Vice President of Business Development, Dr. William Toreki as Vice President of Research & Development, and Nam H. Nguyen, Chief Financial Officer. Roy Carr joined Quick-Med in 2005 and has been serving as Director of Business Development since that time. Bill Toreki joined the Company in 2002 and is the lead inventor on seven of the Company's patents. He previously served as Quick-Med's Chief Scientist. Nam Nguyen, Chartered Global Management Accountant, has been CFO of Quick-Med since 2004.
The Company also announced that CEO Ladd Greeno and Vice-President of Research & Development Jerry Olderman would be stepping aside from their management roles in the Company after a short transition period to be completed in mid-August. Both Mr. Greeno and Dr. Olderman will remain active with the Company as members of its Board of Directors and as senior advisors. Mr. Greeno shall also remain as Chairman of the Board.
Additional information can be found in the Company's current report on Form 8-K filed with the Securities and Exchange Commission and available on the Company's website within the next few days.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing proprietary, broad-based technologies for infection prevention and control in the consumer and healthcare markets. In addition to NIMBUS, Quick-Med's Stay Fresh® technology provides highly durable antimicrobial protection for laundered apparel and other textile applications and its NimbuDerm™ technology is being developed as a long-lasting hand sanitizer. For more information, see: www.quickmedtech.com.
© 2012 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® and Stay Fresh® are registered trademarks and NimbuDerm™ is a trademark of Quick-Med Technologies, Inc.
Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.
J. Ladd Greeno
(888) 835.2211 Ext. 102